Key Points
- CEO August Troendle sold 21,883 Medpace shares for approximately $13.64 million at an average price of $623.29, reducing his stake by 4.34% to 482,390 shares.
- Medpace reported better-than-expected quarterly results, with EPS of $4.25 versus the $3.98 consensus and revenue of $707.33 million, up 17.2% year over year. The company set fiscal 2026 EPS guidance at $17.25–$17.95.
- Analysts maintain a consensus “Hold” rating with a $595.20 target price, although several firms recently raised their targets and 77.98% of the stock is owned by institutional investors.
Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) CEO August Troendle sold 21,883 shares of the company's stock in a transaction on Monday, September 21st. The stock was sold at an average price of $623.29, for a total transaction of $13,639,455.07. Following the transaction, the chief executive officer owned 482,390 shares of the company's stock, valued at approximately $300,668,863.10. This represents a 4.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Medpace Stock Performance
Shares of NASDAQ MEDP opened at $617.15 on Thursday. The firm's fifty day moving average is $591.38 and its two-hundred day moving average is $514.21. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90. The company has a market cap of $17.22 billion, a P/E ratio of 36.18, a P/E/G ratio of 2.81 and a beta of 1.15.
Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating analysts' consensus estimates of $3.98 by $0.27. The firm had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business's quarterly revenue was up 17.2% compared to the same quarter last year. During the same quarter last year, the business posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.
Institutional Trading of Medpace
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Schulhoff & Co. Inc. lifted its stake in shares of Medpace by 1.1% in the 4th quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company's stock valued at $1,237,000 after purchasing an additional 25 shares during the last quarter. Balefire LLC increased its position in shares of Medpace by 6.1% during the 1st quarter. Balefire LLC now owns 451 shares of the company's stock worth $217,000 after purchasing an additional 26 shares during the last quarter. Root Financial Partners LLC increased its position in shares of Medpace by 34.1% during the 1st quarter. Root Financial Partners LLC now owns 122 shares of the company's stock worth $59,000 after purchasing an additional 31 shares during the last quarter. GAMMA Investing LLC raised its holdings in Medpace by 2.8% in the 2nd quarter. GAMMA Investing LLC now owns 1,158 shares of the company's stock valued at $613,000 after buying an additional 32 shares during the period. Finally, Handelsbanken Fonder AB raised its holdings in Medpace by 0.6% in the 2nd quarter. Handelsbanken Fonder AB now owns 7,020 shares of the company's stock valued at $3,718,000 after buying an additional 40 shares during the period. 77.98% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several equities research analysts recently weighed in on MEDP shares. Jefferies Financial Group restated a "hold" rating on shares of Medpace in a research report on Monday, September 14th. Mizuho increased their price target on shares of Medpace from $586.00 to $665.00 and gave the company an "outperform" rating in a report on Friday, July 24th. Royal Bank Of Canada boosted their price objective on Medpace from $484.00 to $692.00 and gave the stock an "outperform" rating in a research note on Friday, July 24th. BMO Capital Markets raised their price objective on Medpace from $400.00 to $600.00 and gave the company a "market perform" rating in a research note on Friday, July 24th. Finally, Weiss Ratings upgraded Medpace from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, August 12th. Three investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, Medpace presently has an average rating of "Hold" and a consensus target price of $595.20.
Read Our Latest Research Report on Medpace
About Medpace
(
Get Free Report)
Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.
Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
